Emerald Mutual Fund Advisers Trust Makes New $4.22 Million Investment in Savara Inc (NASDAQ:SVRA)

Emerald Mutual Fund Advisers Trust acquired a new position in Savara Inc (NASDAQ:SVRA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,375,888 shares of the company's stock, valued at approximately $4,224,000. Emerald Mutual Fund Advisers Trust owned approximately 0.80% of Savara as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Altium Capital Management LLC boosted its position in shares of Savara by 0.3% in the fourth quarter. Altium Capital Management LLC now owns 1,579,000 shares of the company's stock worth $4,848,000 after buying an additional 4,000 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in Savara by 14.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company's stock worth $112,000 after acquiring an additional 4,732 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Savara by 13.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 43,668 shares of the company's stock worth $135,000 after acquiring an additional 5,236 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Savara by 3.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 143,661 shares of the company's stock worth $441,000 after acquiring an additional 5,450 shares during the period. Finally, Barclays PLC raised its stake in shares of Savara by 2.5% during the fourth quarter. Barclays PLC now owns 236,705 shares of the company's stock valued at $728,000 after purchasing an additional 5,700 shares during the period. Hedge funds and other institutional investors own 87.93% of the company's stock.

Savara Stock Up 4.3 %

Shares of SVRA traded up $0.14 during trading on Friday, reaching $3.40. The company's stock had a trading volume of 706,717 shares, compared to its average volume of 1,299,663. Savara Inc has a twelve month low of $2.26 and a twelve month high of $5.31. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. The company has a market cap of $587.34 million, a price-to-earnings ratio of -7.91 and a beta of 0.44. The company has a fifty day moving average of $2.83 and a two-hundred day moving average of $3.06.

Savara (NASDAQ:SVRA - Get Free Report) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). The business had revenue of $0.27 million for the quarter. On average, sell-side analysts predict that Savara Inc will post -0.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a "buy" rating and issued a $6.00 target price on shares of Savara in a research note on Friday, March 28th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, Savara presently has a consensus rating of "Moderate Buy" and a consensus price target of $8.83.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.